Alverine Citrate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Alverine Citrate: Preliminary Screening — Insufficient Data for Full Evaluation
One-Sentence Summary
Alverine Citrate is an antispasmodic smooth muscle relaxant commonly used for irritable bowel syndrome (IBS) and gastrointestinal spasms. However, the current Evidence Pack contains no TxGNN-predicted new indications, no Singapore regulatory registrations, and no mechanism of action data — this report serves as a data-gap assessment, and a Hold decision is recommended until core data is collected.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in Singapore regulatory database |
| Predicted New Indication | No predictions available (TxGNN pipeline not completed) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet generated |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Alverine Citrate in this Evidence Pack. Based on known pharmacological literature, Alverine Citrate is a selective smooth muscle relaxant belonging to the antispasmodic class. Its efficacy in gastrointestinal conditions (particularly IBS and intestinal colic) has been established in clinical practice.
Without a completed TxGNN prediction run, no new indication has been identified. The DrugBank query returned one result (query log ID 2), suggesting the compound exists in the DrugBank database — however, the DrugBank ID was not captured in this Evidence Pack. Completing the DrugBank ID lookup would be the critical first step to enable TxGNN graph traversal and generate repurposing candidates.
Singapore Market Information
Alverine Citrate currently has no registered products in the Singapore Health Sciences Authority (HSA) database. There are no active licenses, withdrawn entries, or historical registrations on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN repurposing pipeline has not been executed for Alverine Citrate, yielding zero predicted indications. Without a DrugBank ID, mechanism of action data, or safety profile, no evidence-based repurposing assessment is possible at this stage.
To proceed, the following is needed:
- [Blocking] Retrieve the DrugBank ID from the DrugBank API (query log confirms the compound exists — ID capture failed)
- [Blocking] Download and parse the package insert (PI) from Singapore HSA or equivalent regional authority to obtain warnings and contraindications
- [High] Extract mechanism of action (MOA) from DrugBank once the ID is confirmed
- [High] Re-run the TxGNN KG prediction pipeline with the confirmed DrugBank ID to generate repurposing candidates
- [Medium] Verify Singapore market status — confirm whether Alverine Citrate is sold under a combination product or under a different INN that may carry its own registration
- [Medium] Run ClinicalTrials.gov and PubMed collectors after TxGNN candidates are generated to populate evidence tables
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.